InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,107.19
(
0.99%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.45
(
0.46%
)
Bitcoin
58,193.57
(
0.76%
)
Post# of 252557
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120016
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 181804

Tuesday, 09/30/2014 12:20:19 PM

Tuesday, September 30, 2014 12:20:19 PM

Post# of 252557
JNJ acquires Alios (private) for $1.75B in cash:

http://finance.yahoo.com/news/johnson-johnson-announces-agreement-acquire-123000575.html

Alios has an RSV drug (AL-8176) in phase-2 and an HCV nuke in preclinical development, as noted in #msg-106165891. JNJ’s PR doesn’t mention the HCV nuke, but it's reasonable to surmise that the HCV nuke influenced the deal value to a non-trivial degree.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up